作为最常见的消化系统肿瘤之一，结直肠癌（CRC）对全球人类健康构成重大威胁。随着免疫治疗和靶向治疗的出现，大多数CRC患者的预后显着改善。然而，携带 BRAF 外显子 15 p.V600E 突变 (BRAFV600E) 的患者并未从这些治疗进展中获得显着的益处。因此，研究人员对这种特定亚型的分子病理学和不同治疗药物组合的临床有效性进行了基础研究。该综述全面总结了BRAF突变结直肠癌独特的分子特征和近期临床研究进展。为了探索潜在的治疗靶点，本文对正在进行的涉及 BRAFV600E 突变 CRC 患者的临床试验进行了系统回顾。© 2024 作者。约翰·威利出版的《临床与转化医学》

As one of the most prevalent digestive system tumours, colorectal cancer (CRC) poses a significant threat to global human health. With the emergence of immunotherapy and target therapy, the prognosis for the majority of CRC patients has notably improved. However, the subset of patients with BRAF exon 15 p.V600E mutation (BRAFV600E) has not experienced remarkable benefits from these therapeutic advancements. Hence, researchers have undertaken foundational investigations into the molecular pathology of this specific subtype and clinical effectiveness of diverse therapeutic drug combinations. This review comprehensively summarised the distinctive molecular features and recent clinical research advancements in BRAF-mutant CRC. To explore potential therapeutic targets, this article conducted a systematic review of ongoing clinical trials involving patients with BRAFV600E-mutant CRC.© 2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.